Krystal Biotech (NASDAQ:KRYS) Given New $218.00 Price Target at Chardan Capital

Krystal Biotech (NASDAQ:KRYS) had its price objective boosted by stock analysts at Chardan Capital from $212.00 to $218.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 16.04% from the company’s current price.

KRYS has been the subject of several other reports. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Price Performance

Shares of KRYS opened at $187.86 on Thursday. The firm’s 50 day moving average is $157.37 and its 200-day moving average is $175.23. The stock has a market capitalization of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS. As a group, equities research analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

Several institutional investors have recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the third quarter worth approximately $40,000. Values First Advisors Inc. acquired a new stake in shares of Krystal Biotech during the third quarter worth approximately $53,000. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $95,000. Huntington National Bank boosted its holdings in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares during the period. Finally, Blue Trust Inc. raised its position in Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after acquiring an additional 412 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).